Michael J. Yee

Axovant Sciences Ltd (NASDAQ: AXON) plummeted 25 percent last week, providing an attractive entry point, as the company is in-licensing two promising orphan gene therapy programs that could have data coming over the next three to 12 months, according to Jefferies. The Analyst Jefferies' analyst...

Encouraging early results from a trial of BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) dwarfism treatment sent the company's shares higher Thursday while analysts boosted their targets. Shares changed hands recently at $138.50, up 12 percent. BioMarin said a trial of its vosoritide drug in...